SAN DIEGO – A session that is scheduled on the final day of a conference usually takes place with a limited audience as delegates leave the event to get an early jump on their travel plans. It is a testament to not only the quality of the speakers but also the subject matter that the Immune-Oncology Drugs: Ready for First Line Therapy? panel at the BIO 2017 conference on Thursday attracted a packed room as well as an overflow one to accommodate all the delegates who wanted to attend. Read More
